Literature DB >> 12007944

Factors affecting risk of symptomatic temporal lobe necrosis: significance of fractional dose and treatment time.

Anne W M Lee1, Dora L W Kwong, Sing Fai Leung, Stewart Y Tung, Wai Man Sze, Jonathan S T Sham, Peter M L Teo, To Wai Leung, Po Man Wu, Rick Chappell, Lester J Peters, John F Fowler.   

Abstract

PURPOSE: To study the factors affecting the risk of symptomatic temporal lobe necrosis after different fractionation schedules. METHODS AND MATERIALS: One thousand thirty-two patients with T1-2 nasopharyngeal carcinoma treated with radical radiotherapy in Hong Kong during 1990-1995 were studied. They were treated at four different centers with similar techniques but different fractionation schedules: 984 patients were given 1 fraction daily throughout (q.d.), and 48 patients were irradiated twice daily (b.i.d.) for part of the course. The median total dose was 62.5 Gy (range 50.4-71.2), dose per fraction was 2.5 Gy (range 1.6-4.2), and overall treatment time (OTT) was 44 days (range 29-70). In addition, 500 patients received supplementary doses for parapharyngeal extension, 113 received booster doses by brachytherapy, and 114 received sequential chemotherapy using cisplatin-based regimes.
RESULTS: Altogether, 24 patients developed symptomatic temporal lobe necrosis: 18 from the q.d. group and 6 from the b.i.d. group. The 5-year actuarial incidence ranged from 0% (after 66 Gy in 33 fractions within 44 days) to 14% (after 71.2 Gy in 40 fractions within 35 days). Multivariate analyses showed that the risk was significantly affected by the fractional effect of the product of total dose and dose per fraction (hazard ratio [HR] = 1.04, 95% confidence interval [CI] 1.02-1.05), OTT (HR 0.88, 95% CI 0.80-0.97), and b.i.d. scheduling (HR 13, 95% CI 3-54). Repeating the analyses for patients treated with the q.d. schedules confirmed the independent significance of OTT in addition to the product of total dose and dose per fraction.
CONCLUSION: The tentative results suggest that in addition to fractional dose, the OTT also had significant impact on the risk of temporal lobe necrosis, and b.i.d. scheduling increased the hazard further.

Entities:  

Mesh:

Year:  2002        PMID: 12007944     DOI: 10.1016/s0360-3016(02)02711-6

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  40 in total

1.  Intensity-modulated radiotherapy for nasopharyngeal carcinoma: improvement of the therapeutic ratio with helical tomotherapy vs segmental multileaf collimator-based techniques.

Authors:  A M Chen; C C Yang; J Marsano; T Liu; J A Purdy
Journal:  Br J Radiol       Date:  2012-01-17       Impact factor: 3.039

2.  Simultaneous integrated vs. sequential boost in VMAT radiotherapy of high-grade gliomas.

Authors:  Mostafa Farzin; Michael Molls; Sabrina Astner; Ina-Christine Rondak; Markus Oechsner
Journal:  Strahlenther Onkol       Date:  2015-09-04       Impact factor: 3.621

Review 3.  Radiation dose-volume effects in the brain.

Authors:  Yaacov Richard Lawrence; X Allen Li; Issam el Naqa; Carol A Hahn; Lawrence B Marks; Thomas E Merchant; Adam P Dicker
Journal:  Int J Radiat Oncol Biol Phys       Date:  2010-03-01       Impact factor: 7.038

4.  Therapeutic doses of cranial irradiation induce hippocampus-dependent cognitive deficits in young mice.

Authors:  Amulya A Nageswara Rao; Hong Ye; Paul A Decker; Charles L Howe; Cynthia Wetmore
Journal:  J Neurooncol       Date:  2011-04-17       Impact factor: 4.130

5.  Temporal lobe injury after re-irradiation of locally recurrent nasopharyngeal carcinoma using intensity modulated radiotherapy: clinical characteristics and prognostic factors.

Authors:  Shuai Liu; Taixiang Lu; Chong Zhao; Jingxian Shen; Yunming Tian; Ying Guan; Lei Zeng; Weiwei Xiao; Shaomin Huang; Fei Han
Journal:  J Neurooncol       Date:  2014-07-02       Impact factor: 4.130

Review 6.  Late temporal lobe necrosis after conventional radiotherapy for carcinoma of maxillary sinus.

Authors:  Madhava R Kanakamedala; Ali Mahta; Jianlin Liu; Santosh Kesari
Journal:  Med Oncol       Date:  2012-01-15       Impact factor: 3.064

Review 7.  Psychiatric Care of the Radiation Oncology Patient.

Authors:  Emily G Holmes; Jordan A Holmes; Eliza M Park
Journal:  Psychosomatics       Date:  2017-04-15       Impact factor: 2.386

8.  Current management strategy of nasopharyngeal carcinoma.

Authors:  William I Wei; Dora L W Kwong
Journal:  Clin Exp Otorhinolaryngol       Date:  2010-03-30       Impact factor: 3.372

9.  Delayed cerebral radiation necrosis following treatment for a plasmacytoma of the skull.

Authors:  Lola B Chambless; Federica B Angel; Ty W Abel; Fen Xia; Kyle D Weaver
Journal:  Surg Neurol Int       Date:  2010-10-25

Review 10.  Radiotherapy for metastatic brain tumors.

Authors:  Yuta Shibamoto; Chikao Sugie; Hiromitsu Iwata
Journal:  Int J Clin Oncol       Date:  2009-08-25       Impact factor: 3.402

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.